Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?

Can J Diabetes. 2016 Oct;40(5):379-381. doi: 10.1016/j.jcjd.2016.08.220.

Authors

Harpreet Singh Bajaj¹, Bernard Zinman²

Affiliations

¹ LMC Diabetes & Endocrinology, Brampton, Ontario, Canada; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
² Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada. Electronic address: zinman@lunenfeld.ca.

PMID: 27737758
DOI: 10.1016/j.jcjd.2016.08.220

No abstract available

MeSH terms

Cardiovascular Diseases / complications*
Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / prevention & control
Clinical Decision-Making*
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Humans
Practice Guidelines as Topic
Treatment Outcome